Skip to main content
OpenTrials
Completed

NCT Number: NCT05472272

Low-Calorie Diets on Type 2 Diabetes Remission

The prevalence of type 2 diabetes mellitus (T2DM) has been increasing rapidly in China. China currently has ~130 million diabetes cases, and over 90% are T2DM. T2DM is a leading cause of morbidity and mortality, posing substantial clinical and public health challenges. Reversing T2DM with a significant amount of weight loss via consuming a low-calorie diet is possible, but no studies have been conducted to determine whether low-calorie diets will help achieve significant weight loss and diabetes remission among Chinese patients with T2DM. The investigators design a pilot study to assess the feasibility of a low-calorie diet intervention program on weight loss and diabetes remission in a Chinese population with T2DM.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Mellitus Body Weight Body Weight Changes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms Weight Loss

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Endocrinology, Shanghai Municipal Hospital of Traditional Chinese Medicine

Shanghai, Shanghai Municipality, 200233, China

About this study

Consistent evidence has shown that overweight and obesity are the leading cause of T2DM, which exacerbates the development of insulin resistance and disease progression. For overweight and obese patients with T2DM, there is a strong consensus that sustained and moderate weight loss can effectively improve glycemic control and blood pressure as well as reduce the need for glucose-lowering medications and improve quality of life.

Short-term dietary interventions using structured low-calorie diets (800-1,000 kcal/day) have shown to be an effective approach for losing weight and promoting sustained diabetes remission in T2DM patients who are overweight or obese. The United Kingdom DiRECT research team designed a structured, intensive intervention program of 12-20 weeks to achieve substantial weight loss and T2DM remission through energy restriction. Researchers recorded ≥15 kg of weight loss in 24% of the participants who underwent a low-calorie formula diet intervention (total diet replacement with 825-853 kcal/day formula low-energy diet meal replacement products). Among these participants, the diabetes remission rate reached 90%.

This non-randomized dietary intervention study comprises 2 study arms: a formula diet (815-835 kcal/day) and a food-based diet (815-835 kcal/day). Participants will be on either of the two low-calorie diets for 12 weeks to achieve at least 12 kg of weight loss (intensive weight loss phase). Participants may extend the weight loss phase if desired. After 12 weeks, participants in the formula diet group are allowed to consume actual meals gradually, and participants in both groups will increase their energy consumption gradually over the next 12 weeks (weight loss achievement and maintenance phase). Physical activity is recommended during the second phase for maintaining weight loss. This study is designed to assess feasibility of the low-calorie diet intervention, in preparation for a full-scale randomized control study. This pilot study also plans to explore potential mechanisms of the intervention for weight loss and diabetes remission.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Physician-diagnosed T2DM
  • Most recent HbA1c level: 6.5%-12.0%
  • Body mass index: 24-45 kg/m2
  • Informed consent signed by participants in this study in accordance with requirements of local regulations and the Ethical Review Committee
  • No plan to leave Shanghai in 2 years

Exclusion criteria

  • Type 1 diabetes
  • Current use of insulin and glucagon-like peptide-1 receptor agonists
  • Major cardiovascular events (e.g., myocardial infarction, stroke, and heart failure) within the previous 6 months
  • Weight loss >5 kg within the past 6 months
  • Diagnosed eating disorders or any dieting behaviors
  • Chronic kidney disease stage 3b or higher (estimated glomerular filtration rate <30 milliliter /min/1.73m2)
  • Previously diagnosed psychiatric disorders, e.g., schizophrenia, post-traumatic stress disorder, obsessive-compulsive disorder, uncontrolled depression, uncontrolled epilepsy
  • Severe arthritis and gout
  • Gallstone disease or known asymptomatic gallstones
  • Participation in another clinical research trial
  • Being pregnant or have a positive pregnancy test result at screening, or have given birth within the past 90 days, or who are breastfeeding.
  • Any known cancers
  • Learning difficulties
  • Alcoholism
  • Pancreatitis

Treatment and study plan

Formula diet

Other

Participants will receive a low-calorie (815-835 kcal/day; approximately 43% carbohydrate, 29% protein, and 29% fat) formula diet product for 12 weeks, followed by a gradual food reintroduction phase combined with physical activity support for 12 weeks.

Food-based diet

Other

Participants will receive a low-calorie (815-835 kcal/day; 45-50% carbohydrate, 20-30% protein, and 20-30% fat) food-based diet created by dietitians for 12 weeks. After 12 weeks, participants will increase energy intake gradually and be encouraged to increase daily physical activity to maintain weight loss for another 12 weeks.

Primary outcomes

  1. Percent of adherence to the intervention

    Time frame: Baseline to 24 weeks

    Percent of adherence is calculated at the end of the intervention by dividing the number of participants who remain in and adhere to the intervention by the total number of participants who participate in the intervention.

  2. Percent of participants achieving significant weight loss and diabetes remission

    Time frame: Baseline to 24 weeks

    Proportion of participants achieving significant weight loss (≥12kg) and diabetes remission, which is defined as having a glycated hemoglobin (HbA1c) level less than 6.5% while receiving no pharmacological therapy for diabetes for at least 3 months, will be estimated at 24 weeks.

Secondary outcomes

  1. Aggregated safety assessment

    Time frame: Baseline to 24 weeks

    Glutathione, glutathione, total bilirubin, direct bilirubin, indirect bilirubin, urea nitrogen, creatinine, blood cell sorting count, urine routine, and adverse events are measured or recorded at the pre-specified time points to reflect number of participants with abnormal laboratory values and/or adverse events that are related to treatment.

  2. Insulin sensitivity

    Time frame: Baseline to 24 weeks

    Insulin sensitivity is evaluated with insulin tolerance tests at the pre-specified time points.

  3. Beta cell function

    Time frame: Baseline to 24 weeks

    Beta cell function is evaluated with arginine stimulation test at the pre-specified time points.

  4. Level of fasting glucose

    Time frame: Baseline to 24 weeks

    Level of fasting glucose is measured using a blood sample from a finger stick when participants have an empty stomach (refraining from eating of drinking any liquids other than water for eight hours) at the pre-specified time points.

  5. Level of postprandial glucose

    Time frame: Baseline to 24 weeks

    Level of postprandial glucose is measured using a blood sample from a finger stick two-hour later after participants eat their meals at the pre-specified time points.

  6. Level of HbA1c

    Time frame: Baseline to 24 weeks

    Level of HbA1c is measured using a blood sample from a finger stick at the pre-specified time points.

  7. Glucose homeostasis

    Time frame: Baseline to 24 weeks

    Time in Range, Time Above Range, and Time Below Range are measured at the pre-specified time points using continuous glucose monitor data.

  8. Body fat composition and fat distribution

    Time frame: Baseline to 24 weeks

    Dual-energy X-ray absorptiometry scan is used for quantifying body composition. Magnetic resonance imaging scan is used to quantify fat in the liver and pancreas at the pre-specified time points.

  9. Gut microbiota

    Time frame: Baseline to 24 weeks

    Metagenomic sequencing of fecal samples is performed to study gut microbiota including bacteria, fungi, archaea, and viruses at the pre-specified time points.

  10. Traditional Chinese Medicine(TCM) tongue diagnosis estimated by tongue-face diagnosis instrument

    Time frame: Baseline to 24 weeks

    Parameters of tongue nature and tongue coating are estimated by tongue-face diagnosis instrument to detect hyperglycemic changes at the pre-specified time points.

  11. TCM facial diagnosis estimated by tongue-face diagnosis instrument

    Time frame: Baseline to 24 weeks

    The changes of face complexion and surface gloss are estimated by tongue-face diagnosis instrument to reveal pathological changes of different viscera and bowels with different natures at the pre-specified time points.

  12. Health-related quality of life

    Time frame: Baseline to 24 weeks

    The European Quality of Life 5-dimension 5-level questionnaire will be used to measure health-related quality of life at the pre-specified time points. The scale is numbered from 0 to 100. 100 measn the best health condition, and 0 means the worst health condition.

  13. Diet

    Time frame: Baseline to 24 weeks

    The food frequency questionnaire will be used to assess diet and eating behaviors at the pre-specified time points.

  14. Binge eating behaviors

    Time frame: Baseline to 24 weeks

    The binge eating scale will be used to assess the presence of binge eating behavior indicative of an eating disorder at the pre-specified time points (less than 17: non-binging; 18-26: moderate binging; 27 and greater: severe binging).

  15. Diet and eating behaviors

    Time frame: Baseline to 24 weeks

    The three-factor eating questionnaire will be used to assess diet and eating behaviors at the pre-specified time points. All items are coded with either 0 or 1 point leading to maximum sum scores of 21 points for the domain of 'cognitive restraint', 16 points for 'disinhibition' and 14 points for 'hunger'. Higher scores indicate stronger characteristic values in the domains.

  16. Psychological status-Anxiety

    Time frame: Baseline to 24 weeks

    The Self-Rating Anxiety Scale will be used to measure anxiety level at the pre-specified time points (20-44 normal range. 45-59 mild to moderate anxiety, 60-74 severe).

  17. Psychological status-Depression

    Time frame: Baseline to 24 weeks

    Patient Health Questionaire-9 will be used to measure depression level at the pre-specified time points (0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe).

  18. Sleep quality

    Time frame: Baseline to 24 weeks

    The Pittsburgh Sleep Quality Index will be used to measure sleep quality at the pre-specified time points. The scores range from 0 to 21 and a score >5 be considered as a significant sleep disturbance. Higher scores indicate worse sleep quality.

  19. Metabolomic profiling performed by liquid chromatography mass spectrometry

    Time frame: Baseline to 24 weeks

    The liquid chromatography mass spectrometry (LC-MS) approach will be used to identify metabolites, pathways and networks that are associated with dietary interventions at the pre-specified time points. The major classes of metabolites including amino acids, carbohydrates, nucleotides, lipids, coenzymes, and cofactors are aggregated to demonstrate metabolic patterns.

Sponsors and collaborators

Lead sponsor

Shanghai Municipal Hospital of Traditional Chinese Medicine

Other

Collaborators

  • Shanghai Jiao Tong University School of Medicine

Registry information

Official study title

Effect of Low-Calorie Diets on Remission of Type 2 Diabetes: A Feasibility Study

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Jul 25, 2022
Registry last updated
May 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.